OverviewSuggest Edit

Retrophin is a biopharmaceutical company which focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, Cholbam and Thiola. The Company also has a number of product candidates to treat various serious diseases.

TypePublic
Founded2011
HQSan Diego, US
Websiteretrophin.com
Employee Ratings4.2

Latest Updates

Employees (est.) (Jan 2019)214(+24%)
Job Openings7
Revenue (FY, 2016)$133.6 M(+34%)
Share Price (Jun 2019)$19.2

Key People/Management at Retrophin

Stephen Aselage

Stephen Aselage

CEO
Laura Clague

Laura Clague

CFO
Neil McFarlane

Neil McFarlane

COO
Show more

Retrophin Office Locations

Retrophin has offices in San Diego, New York, Cambridge and Dublin
San Diego, US (HQ)
3721 Valley Centre Dr #200
Cambridge, US
141 Portland St 10th Floor
New York, US
777 3rd Ave
Dublin, IE
2nd Floor Palmerston House Fenian Street
Show all (4)

Retrophin Financials and Metrics

Retrophin Revenue

Retrophin's revenue was reported to be $133.59 m in FY, 2016 which is a 33.7% increase from the previous period.
USD

Net income (Q2, 2019)

(38.7m)

EBIT (Q2, 2019)

(36.5m)

Market capitalization (10-Jun-2019)

795.6m

Closing stock price (10-Jun-2019)

19.2

Cash (30-Jun-2019)

75.7m
Retrophin's current market capitalization is $795.6 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

28.2m99.9m133.6m

Revenue growth, %

254%34%

Cost of goods sold

571.0k2.2m4.6m3.6m5.5m

Gross profit

27.6m97.7m129.0m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cost of goods sold

900.01.2m197.4k637.0k513.0k757.0k1.0m1.6m709.0k797.0k925.0k1.6m1.2m1.1m1.0m979.0k

General and administrative expense

10.1m11.3m18.6m19.7m22.3m19.1m23.2m23.8m23.1m28.8m24.9m26.5m25.1m26.1m32.7m39.0m

R&D expense

6.9m13.7m13.0m10.6m14.1m14.7m17.7m18.4m20.9m19.5m19.6m24.6m34.5m32.4m33.4m37.9m

Operating expense total

17.0m26.2m31.8m30.9m48.5m37.2m44.7m54.3m48.0m52.4m50.9m56.3m62.9m76.3m77.8m81.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

6.0m18.2m37.8m41.0m99.4m102.9m

Accounts Receivable

8.0m12.5m18.5m13.9m14.5m

Inventories

1.4m813.4k2.5m2.8m5.4m5.6m

Current Assets

7.5m37.3m301.9m332.4m325.8m495.7m
Quarterly
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(33.8m)(110.9m)117.2m(47.9m)(59.7m)(102.7m)

Depreciation and Amortization

216.0k5.4m13.4m16.1m17.8m18.7m

Inventories

(1.3m)237.1k(1.2m)(306.0k)(1.7m)(2.8m)

Accounts Payable

2.8m20.3m3.4m9.7m2.7m(2.7m)
USDY, 2019

Financial Leverage

2.3 x
Show all financial metrics

Retrophin Online and Social Media Presence

Embed Graph

Retrophin News and Updates

Retrophin neurological disorder drug misses late-stage study main goal

Retrophin Inc said on Thursday its treatment for a rare neurological disorder failed to meet the main goal in a late-stage study.

Retrophin paid pharma bro Martin Shkreli to settle legal claims — won't say how much

Martin Shkreli's lawyer told the judge in his criminal case that the "pharma bro" will ask the U.S. Supreme Court to hear an appeal of his fraud conviction.

Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference

SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Wednesday, August 7, 2019 at 8:30 a.m. ET.

Retrophin to Report Second Quarter 2019 Financial Results

SAN DIEGO, July 23, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial re…

Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria

 Enteric-coated formulation offers flexible dosing options, including administration with or without food

Martin Shkreli settles all litigation with his former company Retrophin

Martin Shkreli, the pharmaceutical entrepreneur serving a seven-year prison term for fraud, has settled all outstanding disputes with Retrophin Inc , the biopharmaceutical company he founded in 2011 and which ousted him three years later.
Show more

Retrophin Blogs

Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses

Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses Content Import Wed, 10/03/2018 - 16:31 Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses Oct 3, 2018 This release is a backfill from…

Retrophin Corporate Overview – October 2018

Retrophin Corporate Overview – October 2018 francine.arand… Sun, 09/30/2018 - 21:47 Retrophin Corporate Overview – October 2018 Display "add to calendar" true Event Type Other Corporate Event Categories …

Retrophin Frequently Asked Questions

  • When was Retrophin founded?

    Retrophin was founded in 2011.

  • Who are Retrophin key executives?

    Retrophin's key executives are Stephen Aselage, Laura Clague and Neil McFarlane.

  • How many employees does Retrophin have?

    Retrophin has 214 employees.

  • Who are Retrophin competitors?

    Competitors of Retrophin include Seelos Therapeutics, Ventria Bioscience and Genoa Pharmaceuticals.

  • Where is Retrophin headquarters?

    Retrophin headquarters is located at 3721 Valley Centre Dr #200, San Diego.

  • Where are Retrophin offices?

    Retrophin has offices in San Diego, New York, Cambridge and Dublin.

  • How many offices does Retrophin have?

    Retrophin has 4 offices.